Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM

Table 2

Characteristics of DILI in different regimens.

	SR/IR (n = 1539)	HR-1 (n = 94)	HR-2 (n = 91)	HR-3 (n = 85)
DILI, n (%)	38 (2.5)	7 (7.4)^a	5 (5.5)	3 (3.5)
Hepatocellular pattern of DILI, n (%)	38 (100)	7 (100)	5 (100)	3 (100)
Hospital stay, days
DILI	8.2 ± 4.4	12.1 ± 8.2	9.0 ± 5.2	6.3 ± 0.5
Non-DILI	4.9 ± 2.2^b	7.8 ± 3.6	7.4 ± 3.2	6.8 ± 3.1
Hospital expense, CNY
DILI	6868 ± 3125	25850 ± 21654	15019 ± 6749	10606 ± 837
Non-DILI	5051 ± 2532^b	15967 ± 9808	13469 ± 9823	12688 ± 6337

SR/IR, standard risk/intermediate risk; HR, high risk; DILI, drug-induced liver injury; CNY, China Yuan. Superscripts “a” and “b” represent significant differences () compared with SR/IR and DILI, respectively.